Piesiak Paweł, Brzecka Anna, Kosacka Monika, Passowicz-Muszyńska Ewa, Dyła Tomasz, Jankowska Renata
Akademia Medyczna we Wrocławiu, Klinika Pulmonologii i Nowotworów Płuc.
Pol Merkur Lekarski. 2011 Nov;31(185):270-3.
Chronic obstructive pulmonary disease (COPD) is characterized by the progressive destruction of the extracellular matrix of the lung. Matrix metalloproteinases (MMPs) and their inhibitors, especially tissue inhibitor of matrix metalloproteinase-1 (TIMP-1), play a central role in the lung remodeling in COPD. Their concentrations in the sputum and bronchoalveolar lavage are considered as a sign of the local inflammation in COPD patients. The aim of the study was to evaluate of the MMP-9 and TIMP-1 serum concentration in COPD patients with respect to the correlation with a systemic inflammatory process.
Thirty six COPD patients (29 male and 7 female) were enrolled into the study. Age-matched, healthy 15 subjects (11 male and 4 female) were selected as a control group. Serum levels of MMP-9, TIMP-1 and CRP were measured. The pre- and post-bronchodilator forced expiratory volume in one second (FEV1), forced vital capacity (FVC), and FEV1/FVC ratio were determined. The Spearman correlation was performed.
The serum MMP-9 concentration was significantly higher in the COPD patients than that in the control group (COPD: 194.8 +/- 129.1 ng x ml(-1); control subjects: 11.7 +/- 2.1 ng x ml(-1); p < 0.001). The serum concentration of CRP was significantly higher in the COPD patients than that in the control group (COPD: 14.3 +/- 6.3 ng x ml(-1); control subjects: 6.2 +/- 2.8 ng x ml(-1); p < 0.001). There was statistically significant correlation between the MMP-9 concentration and the CRP level in the serum of patients with COPD (p < 0.01; r = 0.45). There were no significant differences in the serum TIMP-1 concentrations between the control group and COPD patients. There was statistically significant, negative correlation between the FEV1 % of predicted value and the MMP-9 concentration (p = 0.03; r = -0.43).
MMP-9 may play an important role in the systemic inflammatory process in COPD. The serum concentrations of MMP-9 correlate with the stage of COPD.
慢性阻塞性肺疾病（COPD）的特征是肺细胞外基质的进行性破坏。基质金属蛋白酶（MMPs）及其抑制剂，尤其是基质金属蛋白酶-1组织抑制剂（TIMP-1），在COPD的肺重塑中起核心作用。它们在痰液和支气管肺泡灌洗中的浓度被视为COPD患者局部炎症的一个标志。本研究的目的是评估COPD患者血清中MMP-9和TIMP-1浓度与全身炎症过程的相关性。
36例COPD患者（29例男性和7例女性）纳入研究。选择15例年龄匹配的健康受试者（11例男性和4例女性）作为对照组。测量血清中MMP-9、TIMP-1和CRP的水平。测定支气管扩张剂使用前和使用后一秒用力呼气量（FEV1）、用力肺活量（FVC）以及FEV1/FVC比值。进行Spearman相关性分析。
COPD患者血清MMP-9浓度显著高于对照组（COPD：194.8±129.1 ng·ml⁻¹；对照组受试者：11.7±2.1 ng·ml⁻¹；p<0.001）。COPD患者血清CRP浓度显著高于对照组（COPD：14.3±6.3 ng·ml⁻¹；对照组受试者：6.2±2.8 ng·ml⁻¹；p<0.001）。COPD患者血清中MMP-9浓度与CRP水平之间存在统计学显著相关性（p<0.01；r = 0.45）。对照组与COPD患者血清TIMP-1浓度无显著差异。预测值的FEV1%与MMP-9浓度之间存在统计学显著的负相关性（p = 0.03；r = -0.43）。
MMP-9可能在COPD的全身炎症过程中起重要作用。MMP-9的血清浓度与COPD的阶段相关。
